Long-term outcome of percutaneous radiofrequency ablation in recurrent hepatocellular carcinoma after liver transplantation

Yang, Wei; Wu, Hao; Zhang, Zhong-Yi; Lee, Jung‐Chieh; Wang, Song; Wang, Yanjie; Wu, Wei; Chen, Minhua; Yan, Kun

doi:10.1080/02656736.2017.1324179

Cited by 8 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 1-, 3-and 5year OS rates were 68.5%, 40.3%, and 40.3%, respectively. The results were comparable with previous studies, of which 3-year OS rate at 24%-51% was reported [16,17,26]. Moreover, the results of this study revealed that a limited EM before RFA was an independent prognostic factors of OS after RFA.…”

Section: Discussionsupporting

confidence: 90%

“…Moreover, the results of this study revealed that a limited EM before RFA was an independent prognostic factors of OS after RFA. When the analysis was limited to patients without limited EM, the 5-year OS rate was 62.4%, which was superior to the aforementioned studies [16,17,26]. Perhaps, as palliative therapy, there is a limited benefit of RFA for intrahepatic tumors, even the metastases are under control.…”

Section: Discussionmentioning

confidence: 84%

“…survival compared with surgery. Other studies also demonstrated that RFA was feasible and effective for r-HCC after LT [16,17]. However, all the reports had either limited number of samples or short period of follow-ups.…”

Section: Discussionmentioning

confidence: 98%

“…Given the difference in oncological characteristics and patterns of recurrence between non-LT and post-LT situations, as well as the specific immunosuppression status of LT patients, whether RFA is still effective for r-HCC after LT remains indefinite. Nevertheless, few published studies focused on this topic [16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Feasibility and outcomes of percutaneous radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation: a single-center experience

Liu

Huang

Xie

et al. 2020

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose: To evaluate the feasibility, effectiveness, and treatment outcomes of percutaneous radiofrequency ablation (RFA) in the application of intrahepatic recurrent hepatocellular carcinoma (r-HCC) after liver transplantation (LT). Methods: From April 2008 to December 2019, a total of 37 patients (34 male and 3 female, mean age: 48.7 ± 10.5 years) with 61 r-HCCs after LT treated by RFA as a first-line option were enrolled. The technical success, recurrence-free survival (RFS), overall survival (OS) and complications were evaluated. Results: After the first session of RFA, three patients were detected with residual foci. All of them received additional session of RFA and two tumors were successfully ablated. Therefore, the technical success was 97.3% (36/37). During the follow-up period, a total of 7 tumors developed local tumor progression (LTP) after 2.2-10.8 months. The LTP rate was 11.7% for r-HCC in the transplanted liver. The median RFS was 4.8 months (95% confidence interval [CI]: 2.2-7.3 months). The 1-, 3-, and 5-year cumulative OS rates were 68.5%, 40.3%, and 40.3%, respectively. Multivariate analyses revealed that tumor size was the only independent predictor for RFS (hazard ratio [HR] ¼ 2.557, 95% CI, 1.015-6.444; p ¼ .046) and limited extrahepatic metastasis was the only independent prognostic factors of OS after RFA for post-LT r-HCC (HR ¼ 4.031, 95%CI, 1.218-13.339; p ¼ .022). Major complications after RFA occurred in two patients (2/37, 5.4%). Conclusion: Percutaneous RFA is safe and effective for intrahepatic r-HCC after LT, especially for those without limited extrahepatic metastasis.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Feasibility and outcomes of percutaneous radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation: a single-center experience

Liu

Huang

Xie

et al. 2020

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…Enfin la RF est utilisée par certaines équipe comme traitement des récidives intrahépatiques de CHC après transplantation hépatique(67). Cette attitude, si elle n'est pas accompagnée de traitements généraux, est discutable dans le contexte de maladie disséminée.…”

unclassified

Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis

Bouda

Barrau

Raynaud

et al. 2020

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Je remercie le Pr Vilgrain d'avoir accepté de présider ce travail de thèse. Votre bienveillance et vos conseils m'auront permis de m'élever. Je vous remercie d'avoir créé et d'entretenir dans votre service cette ambiance unique, donnant l'envie et le courage de faire, et de bien le faire. Je remercie le Pr de Kerviler d'avoir accepté de juger ce travail de thèse. Je vous remercie de me faire confiance et de me donner l'opportunité de travailler à vos côtés. Cela fait bien trop longtemps que j'attends. Je remercie le Pr De Baere d'avoir accepté de juger ce travail de thèse. Je vous remercie d'inspirer ma génération de radiologues interventionnels. Je remercie le Pr Luciani d'avoir accepté de juger ce travail de thèse. Votre regard et votre expertise sur ces sujets me sont chers. Je remercie mon directeur de m'avoir constamment accompagné et soutenu dans ce projet. Je te remercie surtout d'être bien plus qu'un directeur à mes yeux. Je remercie les différents maîtres, qui année après année ont modelé ma pensée et mon raisonnement : Foucauld, Laure, Sophie, Anne-Laure, Onorina, Bertrand et Jean-Noel. Je remercie l'équipe d'anatomo-pathologie de Foch de m'avoir montré à quel point le diagnostic était primitif en radiologie, et bien sûr pour tout le reste. Je remercie tous les radiologues interventionnels qui ont, si patiemment, accompagnés mes très lents gestes : Kim, Philippe C, Nourrezzamene, Tolis, Mohammed, Carmella, Galadec, Philippe B et Felipe. Je serai un peu de vous tous. Je remercie la fraternité Beaujon de m'avoir accueilli, intégré, fêté, sorti, réintégré et refêté.

show abstract

Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis

Al-Ameri

Zheng

2022

Transplantation Reviews

View full text Add to dashboard Cite

Long-term outcome of percutaneous radiofrequency ablation in recurrent hepatocellular carcinoma after liver transplantation

Abstract: Ultrasound-guided percutaneous RFA of recurrent HCC after LT had a high technical success rate and local control. However, RFA cannot decrease the frequency of new tumours or extrahepatic metastasis. The AFP level and tumour number before RFA should be considered to predict the outcome.

Cited by 8 publications

References 38 publications

Feasibility and outcomes of percutaneous radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation: a single-center experience

Feasibility and outcomes of percutaneous radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma after liver transplantation: a single-center experience

Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis

Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis

Contact Info

Product

Resources

About